LAUSR

Advances in inflammatory skin disease management are rapidly redefining dermatologic practice. This issue presents a compelling framework unifying type 2 inflammation across conditions like atopic dermatitis, prurigo nodularis, and chronic urticaria, emphasizing shared cytokine pathways and therapeutic opportunities. Also featured here is new real‐world evidence supporting dupilumab efficacy following tralokinumab failure. In psoriasis, a novel “step‐down” treatment strategy advocates for earlier biologic use in younger patients, followed by de‐escalation. A paired commentary tempers this proposal with methodological and practical concerns. Finally, data on bimekizumab's safety and effectiveness in patients with chronic kidney disease address a critical clinical gap. These contributions highlight a shift toward precision medicine, integrating immunologic insight with patient age, comorbidity profiles, and therapeutic sequencing to inform truly individualized care.